Elutia (NASDAQ:ELUT - Get Free Report)'s stock had its "overweight" rating reissued by equities researchers at Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. They presently have a $10.00 target price on the stock. Cantor Fitzgerald's target price points to a potential upside of 180.90% from the stock's previous close.
Elutia Trading Down 7.0 %
Shares of Elutia stock traded down $0.27 on Friday, hitting $3.56. 49,936 shares of the company traded hands, compared to its average volume of 41,925. Elutia has a 52 week low of $1.39 and a 52 week high of $5.24. The company has a market cap of $121.25 million, a PE ratio of -1.36 and a beta of 0.76. The stock's 50 day moving average price is $3.75 and its 200-day moving average price is $3.67.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Arcus Capital Partners LLC acquired a new stake in shares of Elutia in the second quarter worth $50,000. Renaissance Technologies LLC grew its stake in Elutia by 50.5% in the 2nd quarter. Renaissance Technologies LLC now owns 53,616 shares of the company's stock valued at $266,000 after acquiring an additional 18,000 shares during the period. Perkins Capital Management Inc. raised its position in Elutia by 9.8% during the third quarter. Perkins Capital Management Inc. now owns 856,552 shares of the company's stock worth $3,263,000 after acquiring an additional 76,450 shares during the period. AIGH Capital Management LLC raised its holdings in shares of Elutia by 288.8% during the second quarter. AIGH Capital Management LLC now owns 1,697,316 shares of the company's stock valued at $8,419,000 after acquiring an additional 1,260,750 shares during the last quarter. Finally, Nantahala Capital Management LLC grew its holdings in shares of Elutia by 8.8% during the second quarter. Nantahala Capital Management LLC now owns 1,795,697 shares of the company's stock worth $8,907,000 after buying an additional 145,697 shares in the last quarter. Hedge funds and other institutional investors own 74.03% of the company's stock.
About Elutia
(
Get Free Report)
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
See Also
Before you consider Elutia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elutia wasn't on the list.
While Elutia currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
